Semax and Selank: reports vs research

Community threads about Semax and Selank often read the same way: a mild stimulant on day one, some appetite suppression, harder-than-usual sleep that night, and a possible lift in mood. Those observations match what people actually report. They do not match what the published research has examined. This article separates the two.

What the research has and has not studied

Semax and Selank are both synthetic heptapeptides developed in Russia and registered there as prescription medicines. Semax is an ACTH(4-7) fragment extended with a Pro-Gly-Pro tail, registered for ischemic stroke recovery and cognitive indications^[4]. Selank is a modified tuftsin analogue registered as an anxiolytic^[5]. Neither is approved by the EMA, the MHRA, or the FDA.

The published research on Semax covers two main areas: neuroprotection after stroke in Russian clinical settings^[4], and rodent mechanistic work on BDNF and dopaminergic signalling^[2][3]. The published research on Selank covers anxiolytic effects compared to benzodiazepines in small Russian trials^[1]. What neither body of work examined is what happens in a healthy young person using both peptides in the same day, at community-forum doses, for subjective cognitive and mood goals.

The stimulant-like effect users report

First-time Semax users commonly describe a wired, alert quality without the sharp peak-and-crash pattern of classical stimulants. The pharmacological explanation most often invoked is Semax's action on dopaminergic and serotoninergic tone. Eremin and colleagues (2005) showed in rodents that Semax elevated striatal serotonin metabolites and amplified the dopaminergic response to a co-administered stimulant^[3]. The compound's basal forebrain binding and BDNF-raising effect, described by Dolotov and colleagues (2006) at 50 to 250 mcg/kg intranasal in rats^[2], adds a growth-factor dimension to that picture.

The problem with mapping those rodent findings to a first-day human experience is that they were conducted at known doses under controlled conditions, and the dose used in rodent mechanistic work is not the same as the spray dose circulating in community forums. No controlled human study has measured catecholamine levels or BDNF in healthy adults after a single community-format dose of Semax.

Appetite suppression: mechanism not established in Semax research

Appetite suppression is a frequent first-day report for Semax. It is not a described endpoint in any published Semax clinical study. The Russian ischemic-stroke work tracked motor recovery, BDNF, and functional scores, not appetite^[4]. The mechanistic rodent work focused on neurotrophins and monoamine systems. Whether Semax suppresses appetite through central catecholaminergic tone, through non-specific arousal, or through something else entirely remains an open question with no published data.

The anxiolytic effect: this is Selank's territory

The reduction in anxious thought loops that users describe pairing Selank with Semax is more directly connected to the published literature than the stimulant or appetite effects. Zozulia and colleagues (2008) conducted a randomised trial in 62 patients with generalised anxiety disorder or neurasthenia, comparing Selank against medazepam, a benzodiazepine^[1]. Anxiolytic effects on Hamilton and Zung scale measures were similar between the two agents. Selank also produced antiasthenic and mild psychostimulant effects that medazepam did not.

A finding from the same study that does not usually make it into community summaries: patients with GAD showed below-normal activity of enkephalin-degrading enzymes at baseline, and Selank treatment raised enkephalin activity. Enkephalins are endogenous opioid peptides involved in mood and stress regulation. That mechanism is not the same as benzodiazepine-type GABA modulation, and it carries different implications for dependence and withdrawal. But it also does not match the simple 'reduces anxiety without sedation' framing that community discussions favour.

Sleep difficulty on the first night

Sleep disruption on day one is a common report for Semax users in particular. The dopaminergic and catecholaminergic activation described in rodent work is consistent with delayed sleep onset if the timing of administration is close to bedtime. No clinical study has specifically examined sleep architecture after Semax. Whether sleep difficulty resolves after the first few doses, persists throughout use, or varies by administration timing is not established in published data. It is one of the known unknowns for this compound in healthy adults.

What we do not yet know

The evidence gaps are worth naming directly. We do not have a characterised dose-response relationship for cognitive or anxiolytic endpoints in healthy adults for either peptide. We do not know how intranasal absorption of either compound compares between individuals. We have no pharmacokinetic data from controlled studies at the doses commonly used outside Russia. We have no safety data on combining Semax and Selank in the same session. The absence of a crash, which users often cite as reassuring, is not the same as absence of effect on monoamine systems over repeated use. The durability of the anxiolytic effect beyond the short Russian trial periods is also uncharacterised.

Regulatory status

Neither Selank nor Semax is authorised as a medicine outside Russia. Neither compound has a marketing authorisation from the EMA, the MHRA in the UK, or the FDA in the US. Both are available through grey-market online channels as research vials or repackaged Russian nasal sprays. That supply chain is not subject to the manufacturing standards, batch testing, or pharmacovigilance obligations that apply to licensed medicines. If you are considering either compound, discussing it with a clinician who knows your health history is the appropriate starting point.